Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Time to hit pause on mitochondria-targeting cancer therapies

Nature Medicine volume 29, pages 29–30 (2023)Cite this article

Subjects

As another clinical trial of a mitochondria-targeting cancer therapy faces failure, it calls for a thorough re-evaluation of the strategy; the time has come to go from the bedside back to the bench.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Targeting metabolism for cancer therapy comes with a cost when the scale is tipped toward intolerable on-target, off-tumor side effects.

References

  1. Stine, Z. E., Schug, Z. T., Salvino, J. M. & Dang, C. V. Nat. Rev. Drug Discov. 21, 141–162 (2022).

    Article  CAS  Google Scholar 

  2. Vasan, K., Werner, M. & Chandel, N. S. Cell Metab. 32, 341–352 (2020).

    Article  CAS  Google Scholar 

  3. Gorelick, A. N. et al. Nat. Metab. 3, 558–570 (2021).

    Article  CAS  Google Scholar 

  4. Yap, T. A. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02103-8 (2023).

    Article  Google Scholar 

  5. Molina, J. R. et al. Nat. Med. 24, 1036–1046 (2018).

    Article  CAS  Google Scholar 

  6. Alistar, A. et al. Lancet Oncol. 18, 770–778 (2017).

    Article  CAS  Google Scholar 

  7. Yen, K. et al. Cancer Discov. 7, 478–493 (2017).

    Article  CAS  Google Scholar 

  8. Wolpaw, A. J. & Dang, C. V. Trends Cell Biol. 28, 201–212 (2018).

    Article  CAS  Google Scholar 

  9. Leone, R. D. et al. Science 366, 1013–1021 (2019).

    Article  CAS  Google Scholar 

  10. Buck, M. D., Sowell, R. T., Kaech, S. M. & Pearce, E. L. Cell 169, 570–586 (2017).

    Article  CAS  Google Scholar 

  11. Pilon-Thomas, S. et al. Cancer Res. 76, 1381–1390 (2016).

    Article  CAS  Google Scholar 

  12. Gong, Y. et al. Cancer Res. Commun. 2, 842–856 (2022).

    Article  Google Scholar 

Download references

Acknowledgements

C.V.D. is supported by the Ludwig Institute for Cancer Research and National Cancer Institute (NCI) grants R01CA252225, R01CA054197 and R01CA057341.

Author information

Authors and Affiliations

  1. Ludwig Institute for Cancer Research, New York, NY, USA

    Xue Zhang & Chi V. Dang

  2. Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA

    Xue Zhang & Chi V. Dang

  3. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Xue Zhang & Chi V. Dang

  4. Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Chi V. Dang

Authors
  1. Xue Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chi V. Dang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chi V. Dang.

Ethics declarations

Competing interests

C.V.D. is consultant for the Barer Institute, Rafael Holdings, Inc. X.Z. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Dang, C.V. Time to hit pause on mitochondria-targeting cancer therapies. Nat Med 29, 29–30 (2023). https://doi.org/10.1038/s41591-022-02129-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-02129-y

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research